Deepshikha Verma

Deepshikha Verma

Auto-generated profile, based on publicly available information

Deepshikha Verma

Department of Pharmacy, Guru Ghasidas Vishwavidyalaya Bilaspur C.G. India, Bilaspur, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2026 in Discover Chemistry
Verified
Journal Article
Open access
PDF file
DVDeepshikha Verma
Deepshikha Verma
BABharti Ahirwar
Bharti Ahirwar
YVYogesh Vaishnav
Yogesh Vaishnav
Background In India and in various regions of Central Asia and Africa, one of the most prevalent deadly and painful hematological disorders is sickle cell anemia, which is a major concern because of less social awareness and no curative treatment available. Disease-carrying individuals have shorter life spans with high morbidity and mortality. To treat and manage the root cause of this disease, novel drug discovery is a necessity. Objective To identify best analogue of proposed derivative of 3,4 di-hydroxycinnamic acid which inhibits hemoglobin polymerization and useful for treatment of Sickle cell Disease. Method A series of analogues were created to determine docking scores of compounds utilizing Auto-Dock Vina software, and later redocking was done by other software to validate the best docked compound. Comparative analysis of binding energies and ADMET profiles of compounds with approved drugs was done to identify the best candidate, and to check stability, in silico simulation studies were performed to determine which would be the most effective, stable, and least hazardous compound. These were then synthesized and biologically assessed. Result We assessed that among the 14 analogues, the C-1 analogue exhibited superior binding affinities after using three software programs for molecular docking analysis. Additionally, MD simulation studies predicted better stability, as most residues in the RMSF were below 4.0 Å, with one base peak at the start and a larger peak observed at 2.0 Å. The radius of gyration remained within the range of 5.2 to 6.0 complex throughout the time period of the 100 ns simulation. Molecular dynamic simulation analysis shows that the complex remains stable all through the action, and the least toxic, better pharmacokinetic profile was assayed through ADMET software and later synthesized in the wet lab, and the newly synthesized compound was confirmed through IR, NMR, and mass data analysis, which also showed better anti-polymerizing activity confirmed through sickle cell-carrying human blood and normal human blood studies; the antioxidant activity of the compound is also confirmed by assay. Conclusion The best activity was shown by Compound C-1 by inhibiting the polymerization of RBCs and having antioxidant activity with a good pharmacokinetic profile than already existing USFDA drugs. Research Highlights Only symptomatic treatment management of drugs is available still. In this study, a novel analogue of 3,4-dihydroxycinnamic acid is showing better results as an anti-sickling activity by inhibiting polymerization of haemoglobin than the already existing approved drug for management of sickle cell anaemia, as it is one of the prevalent genetic hemoglobinopathies. Results are validated through molecular docking studies, molecular dynamic studies, and synthesis of the best compound. Further animal toxicity studies are reported, and anti-sickling activity is shown through human blood studies.

4 September 2026 in Discover Chemistry
Verified
Journal Article
Open access
PDF file
DVDeepshikha Verma
Deepshikha Verma
BABharti Ahirwar
Bharti Ahirwar
YVYogesh Vaishnav
Yogesh Vaishnav
Mayank GarhewalMayank Garhewal
Mayank Garhewal
Introduction Sickle Cell Disease is one of the hemoglobinopathy major pathology behind is vaso -occlusion of RBCs contributing severe complications which has global distribution worldwide. Existing approved drugs available does not promise curative treatment only provides symptomatic relief and repeated intake of medications life-long for healthy survival and periodical blood transfusions doesn’t eradicate the sufferings of individuals, only tedious genetic stem cell transplants are to combat the disease. There is need to discover novel potent anti-sickling agent which inhibits RBCs polymerization and have better anti-oxidant properties. So, two promising hybrid molecules having reported anti-oxidant activity and inhibiting polymerisation of RBCs is the choice for moiety i.e. one is of Phthalimide and other moiety is Caffeic acid from them some newer analogues were developed to discover more effective and less toxic Compounds an anti- sickling agent. Method The Objective of this work was to discover newer better anti-sickling candidates through Computational approach. Best novel analogues of Phthalimide Pharmacophore and Caffeic acid Pharmacophore was formed using bio-isosteric design method and total of 373 analogues were created, each focusing on to get improved Pharmacokinetic Properties and less toxic analogues by using ADMET 3.0 Software and Orisis Software. Molecular docking studies were conducted using Auto Dock Vina Pyrex software followed by ICM pro bowser for visualizing interactions of Protein and Ligand. To analyse stability of compound, Molecular dynamic simulation studies were done using Desmond Schrodinger suite Software. DFT analysis of analogues were done to analysis an electronic stability. Result and discussion The best docking scores of analogues were obtained with better Pharmacokinetic profile, good medicinal properties and low toxicity levels from respective Pharmacophores i.e. P-2 with − 10.4 Kcal/mol and C-2 with − 9.0 Kcal/mol against protein 2HBS. Molecular dynamic Simulation of P-2 and C-2 was conducted, reveals that the complexes-maintained stability through 100ns. DFT calculations was also predicted for the stability and electronic properties of analogues P-2 and C-2 both molecules exhibited distinct conformational stability and unique electronic responses, offering deep insight into their reactivity and molecular functionality. Conclusion Computational approach combining Molecular docking, Molecular dynamic simulation and toxicity promise discovery of better candidates for development of potential anti- sickling agents.

24 March 2026 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
DVDeepshikha Verma
Deepshikha Verma
BABharti Ahirwar
Bharti Ahirwar
YVYogesh Vaishnav
Yogesh Vaishnav